Acquired resistance to cancer immunotherapy

Research output: Contribution to journalReviewResearchpeer-review

Arianna Draghi, Christopher Aled Chamberlain, Andrew Furness, Marco Donia

In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

Original languageEnglish
JournalSeminars in Immunopathology
Pages (from-to)31-40
Publication statusPublished - 2019

ID: 213324486